<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00818129</url>
  </required_header>
  <id_info>
    <org_study_id>D1820C00001</org_study_id>
    <nct_id>NCT00818129</nct_id>
  </id_info>
  <brief_title>Study to Investigate Safety, Tolerability and PK Following Single and Multiple Ascending Doses of AZD7295 in Japanese</brief_title>
  <official_title>A Phase I, Randomized, Double-Blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7295 Following Single and Multiple Ascending Oral Dose Administration in Healthy Male Japanese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to investigate the safety and tolerability of single
      and multiple oral doses of AZD7295 in healthy male Japanese subjects. This will be done by
      comparing the effect of AZD7295 to placebo. The study will aslo investigate the absorption,
      distribution and disappearance of AZD7295 in the body.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AE, safety laboratory test (haematology, clinical chemistry, urinalysis), 12-lead ECG, BP, pulse rate, body temperature</measure>
    <time_frame>During the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Cmax, tmax, AUC, AUC0-t, CL/F, Vss/F, t1/2 , Cmin, Rac, etc)</measure>
    <time_frame>Frequent sampling until 72 hours after single administration in Single Dose Part and until 72 hours after last administration (6 days administration) in Multiple Dose Part</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">62</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD7295</intervention_name>
    <description>ascending single doses (start dose 90 mg), oral solution and then multiple ascending dose (tbd based on single dose results), oral solution</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>multiple ascending dose (tbd based on single dose results), oral solution</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of signed, written and dated informed consent

          -  Healthy male Japanese volunteers aged 20-55 years

          -  BMI between 18 and 27 kg/m2

          -  Have negative screens for HIV, hepatitis B and C viruses and syphilis

        Exclusion Criteria:

          -  Use of prescribed medication within 2 weeks prior to the dose of study medication

          -  Participation in another study that included drug treatment within 16 weeks before the
             start of the present study.

          -  History or presence of gastrointestinal, hepatic or renal disease or a condition known
             to interfere with absorption, distribution, metabolism or excretion of drugs.

          -  History of severe food or drug allergy/hypersensitivity or ongoing
             allergy/hypersensitivity, as judged relevant by the investigator.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Masatoshi Tsukamoto, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyushu Clinical Pharmacolgy Reasearch Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fukuoka-City</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 24, 2008</study_first_submitted>
  <study_first_submitted_qc>January 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2009</study_first_posted>
  <last_update_submitted>July 22, 2009</last_update_submitted>
  <last_update_submitted_qc>July 22, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 23, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dereck Tait, Medical Science Director, Anti-Viral EPT</name_title>
    <organization>Arrow Therapeutic Limited</organization>
  </responsible_party>
  <keyword>Phase I</keyword>
  <keyword>Japan</keyword>
  <keyword>Japanese</keyword>
  <keyword>oral solution</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

